Fundamentals scanner

You are paying 35.8 years of current profit for each share. The earnings yield is 2.8%. The tracked Pharma & Healthcare median is 32.2× (n=7), so this trades richer than its peers.

The market values the company at 5.2× its accounting net worth. High is normal for asset-light businesses and unusual for banks.

This is the only common multiple that accounts for debt — it is what an actual acquirer would look at, because they would inherit the borrowings.

Pays 0.88% of the current price out each year. Remember that yield rises when price falls — check the dividend is covered by cash flow.

Based on the next-year earnings estimate — 27.9× against 35.8× trailing. A forward P/E well below trailing is pricing in an earnings jump; treat the forecast with caution.

You pay 7.2× annual sales. Useful when earnings are depressed or negative and P/E breaks down — but a high multiple needs high margins to justify it.

Not available.

Not available.

Keeps ₹23.2 of operating profit from every ₹100 of sales. Compare only against companies in the same industry.

Sustained high net margins are evidence that something is stopping competitors from competing the profits away.

Keeps ₹78.9 of gross profit per ₹100 of sales, before operating costs. A high, stable gross margin is the clearest single sign of pricing power.

A conservative balance sheet that can absorb a downturn without a crisis.

Not available.

Not available.

Against cash of ₹33516.58 Cr. Net debt is what matters, not gross borrowings.

Not available.

Ask where the growth came from: more volume, higher prices, or an acquisition. They are very different in quality.

Profits are growing faster than sales — margins are expanding, which is the sign of genuine operating leverage.

EBITDA of ₹16583.24 Cr and operating cash flow of —.

P/E divided by expected growth. Only as reliable as that growth forecast, which is usually optimistic.

₹50.32 of profit earned per share over the last twelve months. Price divided by this is the trailing P/E.

The accounting net worth behind each share is ₹348.31; price-to-book compares the market price with this.

Pays out 32% of profit as dividends and retains the rest. Above roughly 85% leaves little to reinvest and is hard to sustain through a weak year.

Market cap plus net debt — closer to what an acquirer actually pays. Against a market cap of ₹4,32,120 Cr.